アブストラクト | With widespread adoption of electronic health records (EHRs), Real World Data and Real World Evidence (RWE) have been increasingly used by FDA for evaluating drug safety and effectiveness. However, integration of heterogeneous drug safety data sources and systems remains an impediment for effective pharmacovigilance studies. In an ongoing project, we have developed a next generation pharmacovigilance signal detection framework known as ADEpedia-on-OHDSI using the OMOP common data model (CDM). The objective of the study is to demonstrate the feasibility of the framework for integrating both spontaneous reporting data and EHR data for improved signal detection with a case study of immune-related adverse events. We first loaded the OMOP CDM with both recent and legacy FAERS (FDA Adverse Event Reporting System) data (from the time period between Jan. 2004 and Dec. 2018). We also integrated the clinical data from the Mayo Clinic EHR system for six oncological immunotherapy drugs. We implemented a signal detection algorithm and compared the timelines of positive signals detected from both FAERS and EHR data. We found that the signals detected from EHRs are 4 months earlier than signals detected from FAERS database (depending on the signal detection methods used) for the ipilimumab-induced hypopituitarism. Our CDM-based approach would be useful to provide a scalable solution to integrate both drug safety data and EHR data to generate RWE for improved signal detection. |
ジャーナル名 | AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science |
Pubmed追加日 | 2020/6/2 |
投稿者 | Yu, Yue; Ruddy, Kathryn J; Wen, Andrew; Zong, Nansu; Tsuji, Shintaro; Chen, Jun; Shah, Nilay D; Jiang, Guoqian |
組織名 | Department of Health Sciences Research, Mayo Clinic, Rochester, MN.;Department of Oncology, Mayo Clinic, Rochester, MN.;Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,;Mayo Clinic, Rochester, MN. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32477694/ |